Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...

180 Life Sciences (ATNF) announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct ...

CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling ...

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human ...

BofA analyst Michael Ryskin lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $72 and keeps a Buy rating on the shares. There were “few surprises” in the formal earnings release ...

Cassava Sciences' stock price jumped 15.5% to $27.13, driven by rising short interest, which now accounts for 35.89% of the total float. he company will hold a conference call on August 8 to discuss ...

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Roivant Sciences (ROIV) to $23 from $20 and keeps a Buy rating on the shares. The company postponed topline data from two Phase 3 ...

UBS raised the firm’s price target on Sight Sciences (SGHT) to $12 from $7 and keeps a Buy rating on the shares. Medicare Administrative Contractors Novitas and First Coast Service Option established ...